The Impact of Gender on Outcomes in Patients With Metastatic Urothelial Carcinoma
Authors:
- Aristotle BamiasABAristotle Bamias
- Susan KregeSKSusan Krege
- Chia-Chi LinCLChia-Chi Lin
- Noah HahnNHNoah Hahn
- Thorsten H. EckeTEThorsten H. Ecke
- Erin MoshierEMErin Moshier
- Guru SonpavdeGSGuru Sonpavde
- James GodboldJGJames Godbold
- William K. OhWOWilliam K. Oh
- Matthew D. GalskyMGMatthew D. Galsky
- 1 September 2013
- journal article
- Published by Elsevier in Clinical Genitourinary Cancer
- Vol. 11 (3) , 346-352
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- Impact of gender on bladder cancer incidence, staging, and prognosisWorld Journal of Urology, 2011
- Phase II Trial of Cisplatin, Gemcitabine, and Bevacizumab As First-Line Therapy for Metastatic Urothelial Carcinoma: Hoosier Oncology Group GU 04-75Journal of Clinical Oncology, 2011
- Sex-specific hormone receptors in urothelial carcinomas of the human urinary bladder: A comparative analysis of clinicopathological features and survival outcomes according to receptor expressionUrologic Oncology: Seminars and Original Investigations, 2011
- Bladder cancer survivals in New South Wales, Australia: why do women have poorer survival than men?BJU International, 2009
- Patterns of Hematuria Referral to Urologists: Does a Gender Disparity Exist?Urology, 2008
- Promotion of Bladder Cancer Development and Progression by Androgen Receptor SignalsJNCI: Journal of the National Cancer Institute, 2007
- Expression of estrogen receptors‐α and ‐β in bladder cancer cell lines and human bladder tumor tissueCancer, 2006
- Weekly cisplatin plus infusional high‐dose 5‐fluorouracil and leucovorin (P‐HDFL) for metastatic urothelial carcinomaCancer, 2006
- Gender differences in stage-adjusted bladder cancer survivalUrology, 2000
- Gender differences in stage distribution of bladder cancerUrology, 2000